Access to Genetic Testing in Underserved Patients With Cancer
Interventional
Phase not listed
USC / Norris Comprehensive Cancer Center
Last Updated: March 18, 2026 Notice- Information is sourced from public registries and may not reflect real-time changes at the local site.
This study compares the experiences of people who receive information about genetic testing from a computer-generated character to patients who receive information from a human genetics healthcare provider. Patients with cancer are increasingly recommended for genetic testing as standard of care. Multiple factors contribute to low usage of genetic testing but for many patients the lack of access to genetic counseling and testing is an important and flexible factor. Lack of access is especially relevant to racial/ethnic minority patients and those living in non-metropolitan rural settings who are frequently cared for at safety-net hospitals with limited genetics services. Alternative delivery models are necessary to improve rates of access to genetic testing in patients with cancer. Health information technology is under used by genetics providers. A patient-facing relational agent (PERLA) will provide pre-test genetics education in both English and Spanish across two clinical settings to facilitate more timely access to genetic testing. Using the PERLA intervention may help researchers learn different ways to provide education about genetic testing to patients with cancer compared to usual care.
* Metastatic or high or very high-risk prostate cancer
* Breast cancer at or before age 50
* Bilateral breast cancer
* Triple negative breast cancer
* Male breast cancer OR
* Healthcare provider who treats patients with any of the above types of cancer
* Able to read and write in English or Spanish
* Able to provide informed consent
Exclusion Criteria
* Patients who cannot provide informed consent
* Patients who cannot see, read, or write
* Patients who have the cancer and clinical characteristics defined in the inclusion criteria, but who do not speak English or Spanish
* Patients with none of the listed cancer diagnoses and clinical characteristics
* Healthcare provider who do not treats cancer patients
Do you think this trial is incorrectly appearing?
Design Details
AllocationRandomized
Intervention ModelParallel Assignment
MaskingNone (Open Label)
Number to Enroll800
Arms & Interventions
Arms
Interventions
Type: Experimental
Description: Patients receive access to PERLA comprising pre-test genetics education and standard post-test provider-based genetic counseling over 20-60 minutes. .
Interventions:
Survey Administration
Electronic Health Record Review
Interview
Best Practice
Educational Intervention
Genetic Counseling
Outcome Measures
Primary Outcome Measures
Proportion of participants who receive genetic testingUp to 3 months
The proportion of participants who receive genetic testing will be reported.
Secondary Outcome Measures
Patient-reported outcomesUp to 3 months
Correlations with patient level factors, such as education, literacy, acculturation, and language will be examined.